News | SPECT Imaging | February 18, 2022

Already used in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) for adult patients, Rapiscan is now approved for use in stress cardiac magnetic resonance imaging (CMR)

Already used in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) for adult patients, Rapiscan is now approved for use in stress cardiac magnetic resonance imaging (CMR)

February 18, 2022 — GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) for additional imaging modalities for its stress agent Rapiscan (Regadenoson). Already an established pharmacological stress agent in SPECT MPI for adult patients, Rapiscan is now approved for use in Magnetic Resonance Imaging (MRI) as well as Computed Tomography (CT) and Positron Emission Tomography (PET).

Rapiscan simulates the effects of exercise in the hearts of adult patients unable to exercise and is used to aid the diagnosis of coronary artery disease (CAD). The approval for additional imaging modalities will enable Rapiscan to be used with an MR contrast agent in stress CMR to assess the function and blood flow of the heart, enabling radiologists/cardiologists to perform a single stress/rest/MRI protocol.

Stress CMR has shown high diagnostic performance (sensitivity and specificity of 90% and above) compared to gold standard invasive imaging for coronary artery disease and is recommended for use in the 2019 European Society of Cardiology guidelines for the diagnosis and management of chronic coronary syndromes, along with other non-invasive diagnostic tests, such as stress SPECT MPI.

Rapiscan can be used across a broad spectrum of patients as it does not require weight and age-based modifications or an infusion pump.

Dr Gianluca Pontone, Director of Cardiovascular Imaging Department, Monzino Cardiology Center at University of Milan said: “Our experience with Rapiscan in stress MR was very positive. We found it easy to use and very effective in helping to speed up the entire examination which was a key factor for us as was the high level of tolerance amongst patients.”

Dr Mark Hibberd, Chief Medical Officer at GE Healthcare Pharmaceutical Diagnostics, said: “Market authorization of the additional imaging modalities for Rapiscan could make it easier for more patients, who are unable to exercise, to have this stress test and aid radiologists and cardiologists in making assessments.”

GE Healthcare has the commercial rights to promote Rapiscan excluding US, Mexico and Canada.

GE Healthcare Pharmaceutical Diagnostics imaging agents support three patient procedures every second worldwide across MRI, X-ray/CT and nuclear medicine imaging. Its portfolio of cardiology products aims to support diagnosis and monitoring throughout the cardiac care pathway and aid treatment decisions across multiple pathologies with products available for use in interventional angiography laboratories, and in CT, MRI, Echocardiography and SPECT imaging.

For more information: www.gehealthcare.com

Related content:

FDA Adds Coronary CT Angiography Indication for GE Healthcare’s Visipaque Contrast Media

Deep Learning with SPECT Accurately Predicts Major Adverse Cardiac Events


Related Content

News | Artificial Intelligence

November 29, 2022 — Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10 ...

Time November 29, 2022
arrow
News | Digital Radiography (DR)

November 28, 2022 — Konica Minolta Healthcare Americas, Inc., a leader in medical diagnostic imaging and healthcare ...

Time November 28, 2022
arrow
News | RSNA

Nov. 27, 2022 — ClariPi Inc. has announced that its ClariCT.AI software will be released on Siemens Healthineers’ ...

Time November 27, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 17, 2022 — HeartVista, a pioneer in AI-assisted MRI solutions, and Siemens Healthineers, a global leader in ...

Time November 17, 2022
arrow
Feature | Contrast Media | By Shankar Khatkale

According to a recent study from market research firm Graphical Research, the global imaging agents market size is set ...

Time November 02, 2022
arrow
News | PET-CT

October 24, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...

Time October 24, 2022
arrow
News | Ultrasound Imaging

October 13, 2022 — A new device in the works at the Beckman Institute for Advanced Science and Technology could make ...

Time October 13, 2022
arrow
News | PET-CT

September 28, 2022 — Xoran Technologies is engaged in a ground-breaking research project to develop a PET/CT scanner for ...

Time September 28, 2022
arrow
News | Artificial Intelligence

September 22, 2022 — Medical imaging specialist Avicenna.AI announced a groundbreaking partnership with the MedTech ...

Time September 22, 2022
arrow
News | PET-CT

September 13, 2022 — For over 40 years the vision of Shared Medical Services (SMS) has been to provide innovative ...

Time September 13, 2022
arrow
Subscribe Now